Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex | Congenital Defects | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis ComplexA Placebo-Controlled Randomized Clinical Trial

Educational Objective
To determine whether add-on cannabidiol is superior to placebo in reducing the number of seizures associated with tuberous sclerosis complex.
1 Credit CME
Key Points

Question  Is add-on cannabidiol superior to placebo in reducing the number of seizures associated with tuberous sclerosis complex?

Findings  In this randomized clinical trial, 224 patients with tuberous sclerosis complex were treated with cannabidiol (25 or 50 mg/kg/day) or matched placebo for 16 weeks. The percentage reduction in the type of seizures regarded as the primary end point was 27% for placebo, 49% for 25 mg/kg/day of cannabidiol, and 48% for 50 mg/kg/day of cannabidiol; a dosage of 25 mg/kg/day led to fewer adverse events than the 50-mg/kg/day dosage.

Meaning  In this study, both cannabidiol dosages were equally efficacious in reducing tuberous sclerosis complex–associated seizures compared with placebo, but the smaller dosage led to fewer adverse events.

Abstract

Importance  Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as tuberous sclerosis complex (TSC).

Objective  To evaluate efficacy and safety of 25-mg/kg/day and 50-mg/kg/day cannabidiol dosages vs placebo against seizures associated with TSC.

Design, Setting, and Participants  This double-blind, placebo-controlled randomized clinical trial (GWPCARE6) enrolled patients between April 6, 2016, and October 4, 2018; follow-up was completed on February 15, 2019. The trial was conducted at 46 sites in Australia, Poland, Spain, the Netherlands, United Kingdom, and United States. Eligible patients (aged 1-65 years) were those with a clinical diagnosis of TSC and medication-resistant epilepsy who had had at least 8 TSC-associated seizures during the 4-week baseline period, with at least 1 seizure occurring in at least 3 of the 4 weeks, and were currently taking at least 1 antiepileptic medication.

Interventions  Patients received oral cannabidiol at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or a matched placebo for 16 weeks.

Main Outcomes and Measures  The prespecified primary outcome was the change from baseline in number of TSC-associated seizures for cannabidiol vs placebo during the treatment period.

Results  Of 255 patients screened for eligibility, 31 were excluded and 224 were randomized. Of the 224 included patients (median [range] age, 11.4 [1.1-56.8] years; 93 female patients [41.5%]), 75 were randomized to CBD25, 73 to CBD50, and 76 to placebo, with 201 completing treatment. The percentage reduction from baseline in the type of seizures considered the primary end point was 48.6% (95% CI, 40.4%-55.8%) for the CBD25 group, 47.5% (95% CI, 39.0%-54.8%) for the CBD50 group, and 26.5% (95% CI, 14.9%-36.5%) for the placebo group; the percentage reduction from placebo was 30.1% (95% CI, 13.9%-43.3%; P < .001) for the CBD25 group and 28.5% (95% CI, 11.9%-42.0%; nominal P = .002) for the CBD50 group. The most common adverse events were diarrhea (placebo group, 19 [25%]; CBD25 group, 23 [31%]; CBD50 group, 41 [56%]) and somnolence (placebo group, 7 [9%]; CBD25 group, 10 [13%]; CBD50 group, 19 [26%]), which occurred more frequently with cannabidiol than placebo. Eight patients in CBD25 group, 10 in CBD50 group, and 2 in the placebo group discontinued treatment because of adverse events. Twenty-eight patients taking cannabidiol (18.9%) had elevated liver transaminase levels vs none taking placebo.

Conclusions and Relevance  Cannabidiol significantly reduced TSC-associated seizures compared with placebo. The 25-mg/kg/day dosage had a better safety profile than the 50-mg/kg/day dosage.

Trial Registration  ClinicalTrials.gov Identifier: NCT02544763

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: October 4, 2020.

Published Online: December 21, 2020. doi:10.1001/jamaneurol.2020.4607

Corresponding Author: Elizabeth A. Thiele, MD, PhD, Pediatric Epilepsy Program, Massachusetts General Hospital, 175 Cambridge St, Ste 340, Boston, MA 02114 (ethiele@mgh.harvard.edu).

Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2020 Thiele EA et al. JAMA Neurology.

Author Contributions: Drs Thiele and Knappertz had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Thiele, Jansen, Kotulska, O'Callaghan, Checketts.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Bhathal, Jansen, Lawson, Wong, Sahebkar, Checketts, Knappertz.

Critical revision of the manuscript for important intellectual content: Thiele, Bebin, Bhathal, Jansen, Kotulska, Lawson, O'Callaghan, Wong, Sahebkar, Knappertz.

Statistical analysis: Checketts, Knappertz.

Administrative, technical, or material support: Jansen, Sahebkar.

Supervision: Thiele, Bhathal, Jansen, Sahebkar, Knappertz.

Conflict of Interest Disclosures: Dr Thiele received support from GW Research Ltd as a site principal investigator during the conduct of the trial; outside of the current work, Dr Thiele serves as a principal investigator on clinical trials for GW Research Ltd and Zogenix and as a consultant for Aquestive Therapeutics, Biocodex, West Therapeutics, Greenwich Biosciences, and Zogenix. Dr Bebin received support from GW Research Ltd as a site principal investigator during the conduct of the trial and serves as a consultant for Greenwich Biosciences and Biocodex. Dr Jansen was a site principal investigator on this trial. Dr Bhathal reported having participated as a principal investigator in the clinical trials used as data for this article. Dr Kotulska reported personal fees and nonfinancial support from GW Pharmaceutical Companies during the conduct of the study. Dr Lawson reported grants from GW Pharmaceutical Companies during the conduct of the study. Dr O'Callaghan reported personal fees from GW Pharmaceutical Companies during the conduct of the study and personal fees from Novartis outside the submitted work. Dr Wong was a site principal investigator on this trial, for which his institution received support from GW Research Ltd. Dr Sahebkar is a full-time employee of Greenwich Biosciences. Mr Checketts is a full-time employee of GW Research Ltd and reports other support from GW Pharmaceutical Companies outside the submitted work. Dr Knappertz is a full-time employee of Greenwich Biosciences and owns shares in the company. In addition, Dr Knappertz had a patent to Use of Cannabinoids in the Treatment of Epilepsy issued and had additional related patents pending (WO2019097238, WO2019106386, WO2019064031, and WO2019145700, as well as unpublished patent documents PCT/GB2019/051173, GB1818935.7, GB1819573.5, GB1900797.0, GB1902427.2, GB1906261.1, GB1907283.4, and GB1910803.4). No other disclosures were reported.

Funding/Support: The study was supported by GW Research Ltd.

Role of the Funder/Sponsor: GW Research Ltd was responsible for the design and conduct of the study (following input from investigators and other experts); the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This included management, monitoring, pharmacovigilance, data analysis, and study medication supply. The trial protocol and procedures were reviewed prior to trial start at investigators’ meetings. Third-party services were used for clinical and bioanalytical laboratory analyses; case report form design; data management; trial medication distribution, returns, and destruction; an interactive voice-response system; seizure type classification; and translation of documents.

Group Information: Members of the GWPCARE6 Study Group are listed in Supplement 3.

Meeting Presentation: Data from this study were previously presented at the American Epilepsy Society Annual Meeting; December 7, 2019; Baltimore, Maryland.

Data Sharing Statement: See Supplement 4.

Additional Contributions: The authors would like to thank the patients, their families, and the sites that participated in this trial sponsored by GW Research Ltd, a GW Pharmaceuticals PLC company. Medical writing and editorial support were provided by Ritu Pathak, PhD, and Mary Kacillas, Ashfield Healthcare Communications, and was funded by GW Research Ltd.

References
1.
Northrup  H , Krueger  DA ; International Tuberous Sclerosis Complex Consensus Group.  Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.   Pediatr Neurol. 2013;49(4):243-254. doi:10.1016/j.pediatrneurol.2013.08.001PubMedGoogle ScholarCrossref
2.
Chan  JA , Zhang  H , Roberts  PS ,  et al.  Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.   J Neuropathol Exp Neurol. 2004;63(12):1236-1242. doi:10.1093/jnen/63.12.1236PubMedGoogle ScholarCrossref
3.
Curatolo  P , Bombardieri  R , Jozwiak  S .  Tuberous sclerosis.   Lancet. 2008;372(9639):657-668. doi:10.1016/S0140-6736(08)61279-9PubMedGoogle ScholarCrossref
4.
Crino  PB , Nathanson  KL , Henske  EP .  The tuberous sclerosis complex.   N Engl J Med. 2006;355(13):1345-1356. doi:10.1056/NEJMra055323PubMedGoogle ScholarCrossref
5.
Wang  S , Fallah  A .  Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options.   Neuropsychiatr Dis Treat. 2014;10:2021-2030.PubMedGoogle Scholar
6.
National Institute of Neurological Disorders and Stroke. Tuberous sclerosis fact sheet. Published 2019. Accessed July 10, 2019. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Tuberous-Sclerosis-Fact-Sheet
7.
Osborne  JP , Fryer  A , Webb  D .  Epidemiology of tuberous sclerosis.   Ann N Y Acad Sci. 1991;615:125-127. doi:10.1111/j.1749-6632.1991.tb37754.xPubMedGoogle ScholarCrossref
8.
Kingswood  JC , d’Augères  GB , Belousova  E ,  et al; TOSCA consortium and TOSCA investigators.  TuberOus SClerosis registry to increase disease Awareness (TOSCA)—baseline data on 2093 patients.   Orphanet J Rare Dis. 2017;12(1):2. doi:10.1186/s13023-016-0553-5PubMedGoogle ScholarCrossref
9.
Tuberous Sclerosis Alliance. Diagnosis, surveillance, and management for healthcare professionals. Accessed July 10, 2019. https://www.tsalliance.org/healthcare-professionals/diagnosis/
10.
Jeong  A , Wong  M .  Systemic disease manifestations associated with epilepsy in tuberous sclerosis complex.   Epilepsia. 2016;57(9):1443-1449. doi:10.1111/epi.13467PubMedGoogle ScholarCrossref
11.
de Vries  PJ , Wilde  L , de Vries  MC , Moavero  R , Pearson  DA , Curatolo  P .  A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).   Am J Med Genet C Semin Med Genet. 2018;178(3):309-320. doi:10.1002/ajmg.c.31637PubMedGoogle ScholarCrossref
12.
de Vries  PJ , Belousova  E , Benedik  MP ,  et al; TOSCA Consortium and TOSCA Investigators.  TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study.   Orphanet J Rare Dis. 2018;13(1):157. doi:10.1186/s13023-018-0901-8PubMedGoogle ScholarCrossref
13.
Chu-Shore  CJ , Major  P , Camposano  S , Muzykewicz  D , Thiele  EA .  The natural history of epilepsy in tuberous sclerosis complex.   Epilepsia. 2010;51(7):1236-1241. doi:10.1111/j.1528-1167.2009.02474.xPubMedGoogle ScholarCrossref
14.
Curatolo  P , Nabbout  R , Lagae  L ,  et al.  Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations.   Eur J Paediatr Neurol. 2018;22(5):738-748. doi:10.1016/j.ejpn.2018.05.006PubMedGoogle ScholarCrossref
15.
Amin  S , Lux  A , Calder  N , Laugharne  M , Osborne  J , O’callaghan  F .  Causes of mortality in individuals with tuberous sclerosis complex.   Dev Med Child Neurol. 2017;59(6):612-617. doi:10.1111/dmcn.13352PubMedGoogle ScholarCrossref
16.
Greenwich Biosciences Inc. Epidiolex (cannabidiol) oral solution. Published October 2020. Accessed November 16, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210365s008lbl.pdff
17.
GW Pharma Ltd. Epidyolex (cannabidiol) oral solution. Published October 4, 2019. Accessed August 19, 2020. https://www.medicines.org.uk/emc/product/10781
18.
Devinsky  O , Cross  JH , Laux  L ,  et al; Cannabidiol in Dravet Syndrome Study Group.  Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.   N Engl J Med. 2017;376(21):2011-2020. doi:10.1056/NEJMoa1611618PubMedGoogle ScholarCrossref
19.
Devinsky  O , Patel  AD , Thiele  EA ,  et al; GWPCARE1 Part A Study Group.  Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.   Neurology. 2018;90(14):e1204-e1211. doi:10.1212/WNL.0000000000005254PubMedGoogle ScholarCrossref
20.
Devinsky  O , Patel  AD , Cross  JH ,  et al; GWPCARE3 Study Group.  Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome.   N Engl J Med. 2018;378(20):1888-1897. doi:10.1056/NEJMoa1714631PubMedGoogle ScholarCrossref
21.
Thiele  EA , Marsh  ED , French  JA ,  et al; GWPCARE4 Study Group.  Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.   Lancet. 2018;391(10125):1085-1096. doi:10.1016/S0140-6736(18)30136-3PubMedGoogle ScholarCrossref
22.
Hess  EJ , Moody  KA , Geffrey  AL ,  et al.  Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.   Epilepsia. 2016;57(10):1617-1624. doi:10.1111/epi.13499PubMedGoogle ScholarCrossref
23.
Miller  I , Scheffer  IE , Gunning  B ,  et al; GWPCARE2 Study Group.  Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial.   JAMA Neurol. 2020;77(5):613-621. doi:10.1001/jamaneurol.2020.0073PubMedGoogle ScholarCrossref
24.
Morrison  G , Crockett  J , Blakey  G , Sommerville  K .  A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects.   Clin Pharmacol Drug Dev. 2019;8(8):1009-1031. doi:10.1002/cpdd.665PubMedGoogle ScholarCrossref
25.
Geffrey  AL , Pollack  SF , Bruno  PL , Thiele  EA .  Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.   Epilepsia. 2015;56(8):1246-1251. doi:10.1111/epi.13060PubMedGoogle ScholarCrossref
26.
Ebrahimi-Fakhari  D , Agricola  KD , Tudor  C , Krueger  D , Franz  DN .  Cannabidiol elevates mechanistic target of rapamycin inhibitor levels in patients with tuberous sclerosis complex.   Pediatr Neurol. 2020;105:59-61. doi:10.1016/j.pediatrneurol.2019.11.017PubMedGoogle ScholarCrossref
27.
Leino  AD , Emoto  C , Fukuda  T , Privitera  M , Vinks  AA , Alloway  RR .  Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus.   Am J Transplant. 2019;19(10):2944-2948. doi:10.1111/ajt.15398PubMedGoogle ScholarCrossref
28.
Ewing  LE , Skinner  CM , Quick  CM ,  et al.  Hepatotoxicity of a cannabidiol-rich cannabis extract in the mouse model.   Molecules. 2019;24(9):1694. doi:10.3390/molecules24091694PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close